Selimoglu-Buet Dorothée, Wagner-Ballon Orianne, Saada Véronique, Bardet Valérie, Itzykson Raphaël, Bencheikh Laura, Morabito Margot, Met Elisabeth, Debord Camille, Benayoun Emmanuel, Nloga Anne-Marie, Fenaux Pierre, Braun Thorsten, Willekens Christophe, Quesnel Bruno, Adès Lionel, Fontenay Michaela, Rameau Philippe, Droin Nathalie, Koscielny Serge, Solary Eric
INSERM U1009, Gustave Roussy, Villejuif, France; Faculty of Medicine, University Paris-Sud, Le Kremlin-Bicêtre, France;
Assistance Publique-Hôpitaux de Paris, Département d'Hématologie et d'Immunologie Biologiques, Hôpital Henri Mondor, Créteil, France; Faculté de Médecine, Université Paris-Est Créteil, Créteil, France;
Blood. 2015 Jun 4;125(23):3618-26. doi: 10.1182/blood-2015-01-620781. Epub 2015 Apr 7.
Chronic myelomonocytic leukemia (CMML) is a myelodysplastic syndrome/ myeloproliferative neoplasm whose diagnosis is currently based on the elevation of peripheral blood monocytes to >1 × 10(9)/L, measured for ≥3 months. Diagnosis can be ambiguous; for example, with prefibrotic myelofibrosis or reactive monocytosis. We set up a multiparameter flow cytometry assay to distinguish CD14(+)/CD16(-) classical from CD14(+)/CD16(+) intermediate and CD14(low)/CD16(+) nonclassical monocyte subsets in peripheral blood mononucleated cells and in total blood samples. Compared with healthy donors and patients with reactive monocytosis or another hematologic malignancy, CMML patients demonstrate a characteristic increase in the fraction of CD14(+)/CD16(-) cells (cutoff value, 94.0%). The associated specificity and sensitivity values were 95.1% and 90.6% in the learning cohort (175 samples) and 94.1% and 91.9% in the validation cohort (307 samples), respectively. The accumulation of classical monocytes, which demonstrate a distinct gene expression pattern, is independent of the mutational background. Importantly, this increase disappears in patients who respond to hypomethylating agents. We conclude that an increase in the fraction of classical monocytes to >94.0% of total monocytes is a highly sensitive and specific diagnostic marker that rapidly and accurately distinguishes CMML from confounding diagnoses.
慢性粒单核细胞白血病(CMML)是一种骨髓增生异常综合征/骨髓增殖性肿瘤,目前其诊断基于外周血单核细胞计数升高至>1×10⁹/L,且持续≥3个月。诊断可能存在模糊性;例如,与纤维化前骨髓纤维化或反应性单核细胞增多症鉴别时。我们建立了一种多参数流式细胞术检测方法,以区分外周血单个核细胞和全血样本中CD14⁺/CD16⁻经典单核细胞、CD14⁺/CD16⁺中间型单核细胞和CD14⁻/CD16⁺非经典单核细胞亚群。与健康供者、反应性单核细胞增多症患者或其他血液系统恶性肿瘤患者相比,CMML患者的CD14⁺/CD16⁻细胞比例呈现特征性增加(临界值为94.0%)。在训练队列(175份样本)中,相关的特异性和敏感性值分别为95.1%和90.6%,在验证队列(307份样本)中分别为94.1%和91.9%。表现出独特基因表达模式的经典单核细胞的积累与突变背景无关。重要的是,这种增加在对去甲基化药物有反应的患者中消失。我们得出结论,经典单核细胞比例增加至占总单核细胞的>94.0%是一种高度敏感且特异的诊断标志物,能快速准确地将CMML与混淆诊断区分开来。